CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

A population-based study of 92 clinically recognised risk factors for heart failure: co-occurrence, prognosis and preventive potential Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes Angiotensin–neprilysin inhibition versus enalapril in heart failure Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Clinical epidemiology of heart failure with preserved ejection fraction (HFpEF) in comparatively young hospitalized patients Sex- and Race-Related Differences in Characteristics and Outcomes of Hospitalizations for Heart Failure With Preserved Ejection Fraction

Expert Opinionhttps://academic.oup.com/eurheartj/article-abstract/41/39/3784/5686010?redirectedFrom=fulltext

JOURNAL:Eur Heart J. Article Link

Dilated cardiomyopathy: so many cardiomyopathies!

G Sinagra, PM Elliott, M Merlo et al. Keywords: DCM; LV; HF

ABSTRACT

The current definition of dilated cardiomyopathy (DCM) is relatively simple; namely, a heart muscle disease characterized by left ventricular (LV) or biventricular dilation and systolic dysfunction in the absence of either pressure or volume overload or coronary artery disease sufficient to explain the dysfunction.1 In the last decades, the prognosis of patients with DCM has improved significantly with survival free from death and heart transplantation rising to more than 80% at 8-year follow-up.2 This improvement in outcomes reflects the implementation of pharmacological and non-pharmacological therapeutic strategies, earlier diagnosis due to familial and sport-related screening, and individualized long-term follow-up with continuous restratification of risk.